<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>38 autopsied cases of cerebral sinus-vein <z:mp ids='MP_0005048'>thrombosis</z:mp> (CSVT) in our institute were studied </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, special attention was paid for the evolution and fate of venous <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>18 cases showed hemorrhagic infarction or intracerebral <z:mp ids='MP_0008817'>hematoma</z:mp> (group 1; G 1) </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, no cerebral parenchymal changes were observed in the other 20 cases (group 2; G 2) </plain></SENT>
<SENT sid="4" pm="."><plain>In 13 of 18 cases of G 1, superior sagittal sinus (SSS) were thrombosed </plain></SENT>
<SENT sid="5" pm="."><plain>10 of these 13 cases showed thrombosed cerebral cortical veins (CV) or deep cerebral veins (DV) </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, none of 16 cases of G 1 with thrombosed SSS showed thrombosed CV or DV </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> cases of the solitary <z:mp ids='MP_0005048'>thrombosis</z:mp> of CV or DV (each 2 cases) belong to G 1 </plain></SENT>
<SENT sid="8" pm="."><plain>Venous <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> were divided into three stages according to its process of organization; recent <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> (R), hyalinized <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> (H), organized <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> (O) </plain></SENT>
<SENT sid="9" pm="."><plain>In the venous <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> of G 1, 6 cases were R, 6 were partly H, 6 were partly 0 </plain></SENT>
<SENT sid="10" pm="."><plain>In addition to O, R and H were also observed in group O </plain></SENT>
<SENT sid="11" pm="."><plain>Distribution of various stage of <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> in same case suggested that gradual <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> evolution had occurred before or after the clinical <z:hpo ids='HP_0003674'>onset</z:hpo> in CSVT </plain></SENT>
<SENT sid="12" pm="."><plain>This study suggested: (1) CV or DV occlusion may play an important role for the advent of cerebral parenchymal changes in CSVT </plain></SENT>
<SENT sid="13" pm="."><plain>(2) Gradual <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> evolution after the <z:hpo ids='HP_0003674'>onset</z:hpo> is one of possible causes of slow clinical deteoration after the <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>Therefore, prevention of these <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> propagation with anti-platelet drugs or fibrinolotic therapy should be recommended for the treatment of CSVT </plain></SENT>
<SENT sid="15" pm="."><plain>On the contrary, hyperosmolar agents and <z:chebi fb="40" ids="35498">diuretics</z:chebi> may produce potential risk of <z:hpo ids='HP_0001944'>dehydration</z:hpo>, and as a result, accelerate secondary <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> extension </plain></SENT>
</text></document>